BRCA1 and neoplasm: In the PAOLA trial, 29/114 patients (25.4%) and, in the AGO TR-1 study, 31/393 patients (7.9%) with a BRCA1/2 mutation in the tumor had no mutation in the germline, respectively [23,24].